Published in Ann Intern Med on December 05, 2006
HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis (2009) 3.89
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
Revising expectations from rapid HIV tests in the emergency department. Ann Intern Med (2008) 2.74
The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med (2010) 2.71
Distinguishing signs of opioid overdose and indication for naloxone: an evaluation of six overdose training and naloxone distribution programs in the United States. Addiction (2008) 2.42
The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann Intern Med (2012) 2.34
Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis (2010) 2.28
Costs and consequences of the US Centers for Disease Control and Prevention's recommendations for opt-out HIV testing. PLoS Med (2007) 2.03
Implementing rapid HIV testing with or without risk-reduction counseling in drug treatment centers: results of a randomized trial. Am J Public Health (2012) 1.82
Cost-effectiveness of HIV testing and treatment in the United States. Clin Infect Dis (2007) 1.70
The Epidemiologic and Economic Impact of Improving HIV Testing, Linkage, and Retention in Care in the United States. Clin Infect Dis (2015) 1.69
Who gets tested for HIV in a South African urban township? Implications for test and treat and gender-based prevention interventions. J Acquir Immune Defic Syndr (2011) 1.67
The clinical impact and cost-effectiveness of routine, voluntary HIV screening in South Africa. J Acquir Immune Defic Syndr (2011) 1.67
Emergency provider attitudes and barriers to universal HIV testing in the emergency department. J Emerg Med (2009) 1.57
Consistency of state statutes with the Centers for Disease Control and Prevention HIV testing recommendations for health care settings. Ann Intern Med (2009) 1.56
Routine HIV screening in France: clinical impact and cost-effectiveness. PLoS One (2010) 1.46
A system-wide intervention to improve HIV testing in the Veterans Health Administration. J Gen Intern Med (2008) 1.46
The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men. Clin Infect Dis (2007) 1.43
The Direct Medical Costs of Late Presentation (<350/mm) of HIV Infection over a 15-Year Period. AIDS Res Treat (2011) 1.41
Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. AIDS (2007) 1.34
Routine opt-out HIV testing strategies in a female jail setting: a prospective controlled trial. PLoS One (2009) 1.33
Time to move towards opt-out testing for HIV in the UK. BMJ (2007) 1.33
A prospective controlled trial of routine opt-out HIV testing in a men's jail. PLoS One (2009) 1.32
A Novel Approach to Realizing Routine HIV Screening and Enhancing Linkage to Care in the United States: Protocol of the FOCUS Program and Early Results. JMIR Res Protoc (2014) 1.29
Costs per Diagnosis of Acute HIV Infection in Community-based Screening Strategies: A Comparative Analysis of Four Screening Algorithms. Clin Infect Dis (2015) 1.23
Cost-effectiveness of HIV screening in patients older than 55 years of age. Ann Intern Med (2008) 1.23
Beyond early infant diagnosis: case finding strategies for identification of HIV-infected infants and children. AIDS (2013) 1.21
A US policy perspective on oral preexposure prophylaxis for HIV. Am J Public Health (2011) 1.20
HIV testing in non-traditional settings--the HINTS study: a multi-centre observational study of feasibility and acceptability. PLoS One (2012) 1.18
Prevalence of HIV infection among inpatients and outpatients in Department of Veterans Affairs health care systems: implications for screening programs for HIV. Am J Public Health (2007) 1.10
Evaluation of the sustainability of an intervention to increase HIV testing. J Gen Intern Med (2009) 1.08
Mobile HIV screening in Cape Town, South Africa: clinical impact, cost and cost-effectiveness. PLoS One (2014) 1.07
Averting HIV infections in New York City: a modeling approach estimating the future impact of additional behavioral and biomedical HIV prevention strategies. PLoS One (2013) 1.07
The cost-effectiveness of a modestly effective HIV vaccine in the United States. Vaccine (2011) 1.06
Opt-out testing for stigmatized diseases: a social psychological approach to understanding the potential effect of recommendations for routine HIV testing. Health Psychol (2009) 1.06
Cost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug users. PLoS One (2012) 1.03
Cost-effectiveness of strategies to improve HIV testing and receipt of results: economic analysis of a randomized controlled trial. J Gen Intern Med (2010) 1.01
The cost-effectiveness of rapid HIV testing in substance abuse treatment: results of a randomized trial. Drug Alcohol Depend (2012) 1.01
Price, performance, and the FDA approval process: the example of home HIV testing. Med Decis Making (2009) 1.00
HIV screening in the health care setting: status, barriers, and potential solutions. Mayo Clin Proc (2012) 0.98
HIV/AIDS: AIDS Drug Assistance Programs in the era of routine HIV testing. Clin Infect Dis (2008) 0.95
HIV screening via fourth-generation immunoassay or nucleic acid amplification test in the United States: a cost-effectiveness analysis. PLoS One (2011) 0.94
Characterizing the HIV epidemic in the prairie provinces. Can J Infect Dis Med Microbiol (2012) 0.93
Scope of rapid HIV testing in urban U.S. hospitals. Public Health Rep (2008) 0.93
Opt-out of voluntary HIV testing: a Singapore hospital's experience. PLoS One (2012) 0.92
Morbidity and risk of subsequent diagnosis of HIV: a population based case control study identifying indicator diseases for HIV infection. PLoS One (2012) 0.91
Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USA. HIV Med (2011) 0.89
Written informed-consent statutes and HIV testing. Am J Prev Med (2009) 0.88
Social and behavioral correlates of sexually transmitted infection- and HIV-discordant sexual partnerships in Bushwick, Brooklyn, New York. J Acquir Immune Defic Syndr (2009) 0.86
Cost-effectiveness of HIV screening in STD clinics, emergency departments, and inpatient units: a model-based analysis. PLoS One (2011) 0.86
Who are California's late HIV testers? An analysis of state AIDS surveillance data, 2000-2006. Public Health Rep (2011) 0.86
Discerning patterns of human immunodeficiency virus risk in healthy young adults. Am J Med (2008) 0.85
A cost-effectiveness analysis of alternative HIV retesting strategies in sub-saharan Africa. J Acquir Immune Defic Syndr (2011) 0.85
To screen or not to screen: is that really the question? Ann Intern Med (2006) 0.85
Expanded HIV screening in the United States: what will it cost government discretionary and entitlement programs? A budget impact analysis. Value Health (2010) 0.83
Assessing targeted screening and low rates of HIV testing. Am J Public Health (2010) 0.83
Implications and impact of the new US Centers for Disease Control and prevention HIV testing guidelines. Curr Infect Dis Rep (2008) 0.83
Late diagnosis of HIV infection at two academic medical centers: 1994-2004. AIDS Care (2008) 0.82
Expanded HIV testing coverage is associated with decreases in late HIV diagnoses. AIDS (2015) 0.81
Cost-effectiveness of voluntary HIV screening in Russia. Int J STD AIDS (2009) 0.81
Cost-effectiveness of screening for unhealthy alcohol use with % carbohydrate deficient transferrin: results from a literature-based decision analytic computer model. Alcohol Clin Exp Res (2009) 0.81
Addressing unmet need for HIV testing in emergency care settings: a role for computer-facilitated rapid HIV testing? AIDS Educ Prev (2013) 0.81
Updated CDC guidelines for HIV testing: a review for Wisconsin practitioners. WMJ (2008) 0.80
Assessing the performance of a computer-based policy model of HIV and AIDS. PLoS One (2010) 0.79
Impact of expanded HIV screening. Ann Intern Med (2007) 0.78
Resource utilization and cost-effectiveness of counselor- vs. provider-based rapid point-of-care HIV screening in the emergency department. PLoS One (2011) 0.78
A comparison of network-based strategies for screening at-risk Hispanic/Latino adolescents and young adults for undiagnosed asymptomatic HIV infection. J Adolesc Health (2014) 0.78
A budget impact analysis of rapid human immunodeficiency virus screening in Veterans Administration emergency departments. J Emerg Med (2011) 0.78
Optimizing an HIV testing program using a system dynamics model of the continuum of care. Health Care Manag Sci (2015) 0.78
The changing demographics of women living with HIV/AIDS in southern Alberta from 1982 to 2006. Can J Infect Dis Med Microbiol (2012) 0.75
Impact of expanded HIV screening. Ann Intern Med (2007) 0.75
Dilemma of concepts and strategies for the prevention of spread of HIV in relation to human behavior, law and human rights. J Zhejiang Univ Sci B (2011) 0.75
Initial Health Assessments and HIV Screening under the Affordable Care Act. PLoS One (2015) 0.75
Spillover effects of HIV testing policies: changes in HIV testing guidelines and HCV testing practices in drug treatment programs in the United States. BMC Public Health (2016) 0.75
Assessment and improvement of HIV screening rates in a Midwest primary care practice using an electronic clinical decision support system: a quality improvement study. BMC Med Inform Decis Mak (2016) 0.75
Routine HIV screening in Portugal: clinical impact and cost-effectiveness. PLoS One (2013) 0.75
Optimizing the Timing of HIV Screening as Part of Routine Medical Care. AIDS Patient Care STDS (2017) 0.75
Women's willingness to be tested for human immunodeficiency virus during pregnancy: A review. World J Virol (2015) 0.75
Projected survival gains from revising state laws requiring written opt-in consent for HIV testing. J Gen Intern Med (2011) 0.75
Cost-effectiveness of screening for HIV in primary care: a health economics modelling analysis. Lancet HIV (2017) 0.75
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Expanded screening for HIV in the United States--an analysis of cost-effectiveness. N Engl J Med (2005) 8.49
Long-term persistence in use of statin therapy in elderly patients. JAMA (2002) 7.19
The survival benefits of AIDS treatment in the United States. J Infect Dis (2006) 7.08
Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med (2004) 6.87
The lifetime cost of current human immunodeficiency virus care in the United States. Med Care (2006) 5.87
Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire. N Engl J Med (2006) 5.62
Loss to care and death before antiretroviral therapy in Durban, South Africa. J Acquir Immune Defic Syndr (2009) 5.40
Does preventive care save money? Health economics and the presidential candidates. N Engl J Med (2008) 4.78
The "ART" of linkage: pre-treatment loss to care after HIV diagnosis at two PEPFAR sites in Durban, South Africa. PLoS One (2010) 4.75
Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med (2013) 4.43
When to start antiretroviral therapy in resource-limited settings. Ann Intern Med (2009) 4.31
Medicare and cost-effectiveness analysis. N Engl J Med (2005) 4.20
Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol (2004) 4.20
Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis (2010) 3.96
Who starts antiretroviral therapy in Durban, South Africa?... not everyone who should. AIDS (2010) 3.93
HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis (2009) 3.89
Cost-effectiveness of total knee arthroplasty in the United States: patient risk and hospital volume. Arch Intern Med (2009) 3.84
Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet (2006) 3.60
Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. N Engl J Med (2014) 3.57
Sexual risk, nitrite inhalant use, and lack of circumcision associated with HIV seroconversion in men who have sex with men in the United States. J Acquir Immune Defic Syndr (2005) 3.54
CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr (2006) 3.39
Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis (2009) 3.30
Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA (2003) 3.25
Alcohol consumption and antiretroviral adherence among HIV-infected persons with alcohol problems. Alcohol Clin Exp Res (2004) 3.24
Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA (2006) 3.23
Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst (2004) 3.11
Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med (2013) 3.10
Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. Clin Infect Dis (2008) 3.09
Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol (2002) 3.09
Early infant HIV-1 diagnosis programs in resource-limited settings: opportunities for improved outcomes and more cost-effective interventions. BMC Med (2011) 3.08
Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis (2008) 2.96
Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA (2006) 2.96
Estimating the lost benefits of antiretroviral drug use in South Africa. J Acquir Immune Defic Syndr (2008) 2.93
Routine voluntary HIV testing in Durban, South Africa: the experience from an outpatient department. J Acquir Immune Defic Syndr (2007) 2.91
Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol (2011) 2.83
HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol (2004) 2.78
Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med (2005) 2.60
Randomized, controlled evaluation of a prototype informed consent process for HIV vaccine efficacy trials. J Acquir Immune Defic Syndr (2003) 2.60
Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med (2003) 2.48
HIV incidence determination in the United States: a multiassay approach. J Infect Dis (2012) 2.47
Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis (2005) 2.47
Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis. Med Decis Making (2007) 2.46
The quality of highly regarded adolescent substance abuse treatment programs: results of an in-depth national survey. Arch Pediatr Adolesc Med (2004) 2.45
Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis (2010) 2.45
Optimizing resource allocation in United States AIDS drug assistance programs. Clin Infect Dis (2006) 2.45
Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis. AIDS (2005) 2.39
Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin Infect Dis (2012) 2.38
Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study. Radiology (2008) 2.37
Priorities for screening and treatment of latent tuberculosis infection in the United States. Am J Respir Crit Care Med (2011) 2.36
Impact of obesity and knee osteoarthritis on morbidity and mortality in older Americans. Ann Intern Med (2011) 2.35
HIV/AIDS, undernutrition, and food insecurity. Clin Infect Dis (2009) 2.33
Alcohol consumption and HIV disease progression: are they related? Alcohol Clin Exp Res (2003) 2.32
Predictors of mortality in patients initiating antiretroviral therapy in Durban, South Africa. S Afr Med J (2008) 2.30
Identifying undiagnosed human immunodeficiency virus: the yield of routine, voluntary inpatient testing. Arch Intern Med (2002) 2.30
Cost-effectiveness of treating multidrug-resistant tuberculosis. PLoS Med (2006) 2.28
Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis (2010) 2.28
HIV testing rates and outcomes in a South African community, 2001-2006: implications for expanded screening policies. J Acquir Immune Defic Syndr (2009) 2.24
Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS (2012) 2.19